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ABSTRACT
The goal of this study was to investigate the entrapment of
3 different model proteins (tetanus toxoid, lysozyme, and
insulin) into poly(D,L-lactic acid) and poly(D,L-lactic-co-
glycolic acid) nanoparticles and to address process-related
stability issues. For that purpose, a modified nanoprecipi-
tation method as well as 2 emulsion-based encapsulation
techniques (ie, a solid-in oil-in water (s/o/w) and a double
emulsion (w1/o/w2) method) were used. The main mod-
ification of nanoprecipitation involved the use of a wide
range of miscible organic solvents such as dimethylsulf-
oxide and ethanol instead of the common acetone and
water. The results obtained showed that tetanus toxoid and
lysozyme were efficiently incorporated by the double
emulsion procedure when ethyl acetate was used as solvent
(980% entrapment efficiency), whereas it was necessary to
use methylene chloride to achieve high insulin entrapment
efficiencies. The use of the s/o/w method or the formation
of a more hydrophobic protein-surfactant ion pair did not
improve protein loading. The nanoprecipitation method led
to a homogenous population of small nanoparticles (with
size ranging from ~130 to 560 nm) and in some cases also
improved experimental drug loadings, especially for lyso-
zyme (entrapment efficiency 9 90%). With respect to drug
content determination, a simple and quick matrix-assisted
laser desorption/ionization time-of-flight mass spectrome-
try (MALDI-TOF MS) method provided results very close
to those obtained by reverse phase-high-performance liquid
chromatography. With respect to protein stability, the dura-
tion and intensity of sonication were not a concern for
tetanus toxoid, which retained more than 95% of its anti-
genicity after treatment for 1 minute. Only a high methy-
lene chloride:water ratio was shown to slightly decrease
toxoid antigenicity. Finally, no more than 3.3% of A21 de-
samido insulin and only traces of covalent insulin dimer
were detected in nanoparticles. In conclusion, both the
double emulsion and nanoprecipitation methods allowed
efficient protein encapsulation. MALDI-TOF MS allowed
accurate drug content determination. The manufacturing
processes evaluated did not damage the primary structure
of insulin.
KEYWORDS: double emulsion, entrapment efficiency,
MALDI-TOF MS, nanoparticles, nanoprecipitation, proteinR
INTRODUCTION
The entrapment of proteins into nanoparticles still remains
a difficult task, since each protein is characterized by es-
sential properties (eg, molecular weight, hydrophilicity, sta-
bility) that might be somehow different with respect to
another protein. This situation often hampers protein for-
mulation, because each protein becomes the subject of a
case study. The choice of a correct formulation strategy is
mainly driven by solubility and molecular stability consid-
erations. In this context, the water-in oil-in water (w1/o/w2)
double emulsion method was often used for successfully
encapsulating a wide range of proteins in microparticles,
mostly because it allowed hydrophilic proteins to be dis-
solved in an aqueous w1 phase before the encapsulation
process. However, proteins might be altered to some extent
by interfaces and agitation stress with this method. More-
over, proteins that are insoluble in water (eg, because of an
isoelectric point close to the neutral pH) should rather be
formulated by solubilizing them in a nonaqueous solvent
or by suspending them in an appropriate medium. In this
respect, a benefit of protein suspension over the solution
is that proteins can maintain their secondary and tertiary
structure.1 The solid-in oil-in water (s/o/w) method is used
from time to time as an alternative to the double emul-
sion method, in order to avoid the water-organic solvent
interface during the first emulsification step. Recently, a
modified nanoprecipitation method was optimized so as
to allow hydrophilic and hydrophobic compounds to be
entrapped within small nanoparticles by using miscible
solvents and in the absence of water.2 In this method,
hydrolytic degradation pathways can be minimized and
other factors of instability such as interfaces and high shear-
ing rates are avoided. Moreover, it has been reported, for
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instance, that lysozyme and insulin, which were precipitated
from DMSO, partially unfolded but recovered biological
activity after reconstitution in aqueous media.1 Another
strategy to promote stability is to form a protein-surfactant
complex by means of an ion-pairing technique. Based on
the interaction of an anionic amphiphilic molecule and a
positively charged protein, ion-pairing takes place at sur-
factant concentrations below the critical micelle concen-
tration (CMC) and at a pH below the isoelectric point of
the protein.3,4 Ion-pairing is expected to be an interesting
means for rendering a protein more hydrophobic, for in-
creasing its solubility in organic solvents, and thus for im-
proving its loading into nanoparticles.5,6
The main goal of this study was to systematically assess the
performance of nanoprecipitation and emulsion-based en-
capsulation processes with respect to nanoparticle size and
final drug loading. The traditional nanoprecipitation
method was modified so as to favor protein encapsulation.
Actually, a wide range of miscible organic solvents such as
dimethylsulfoxide (DMSO) and ethanol were used instead
of commonly used acetone and water.2,7-9 Two emulsion-
based encapsulation techniques (ie, a solid-in oil-in water
[s/o/w] and a double emulsion [w1/o/w2] method) were also
used.
Three model proteins, tetanus toxoid (TT), lysozyme, and
insulin, were chosen for this comparative encapsulation in-
vestigation on the basis of their molecular weight (150 kDa,
14 300 Da, and 5777 Da, respectively) and their solubility
in the solvents used. Indeed, TT is a large protein with a
complex molecular structure, whereas lysozyme and insu-
lin are rather small in comparison. Both TT and lysozyme
are soluble in pure water, whereas insulin is only soluble
in acid solutions and in solvents such as DMSO. There-
fore, all these proteins were good candidates for the double
emulsion method. Among these 3 proteins, only TT could
not be encapsulated by nanoprecipitation because of a lack
of solubility in DMSO. In addition, lysozyme and insulin
were ion-paired with sodium oleate and sodium dodecyl-
sulfate (SDS), respectively, in order to determine if the re-
sulting complexes could be more efficiently entrapped into
nanoparticles by the above-mentioned methods than the
native proteins (ion-pairing with TT is not possible).
Some additional stability assays were also performed to
evaluate the effect of these encapsulation methods on
protein stability. For this purpose, some specific analyti-
cal methods were selected according to the protein in-
vestigated. Thus, TT, the main function of which is to
induce an immune response without pathogenic effects,
was evaluated with respect to its antigenic properties
through an indirect enzyme-linked immunosorbent assay
(ELISA). This test was performed after exposure of TT
to the ultrasounds and organic/aqueous interfaces that are
both degradation factors involved during emulsion-based
encapsulation procedures. Concerning insulin, the chemi-
cal degradation due to the encapsulation procedure was
tracked using reverse-phase high performance liquid chro-
matography (RP-HPLC) (detection of deamidated insulin
by-products) and matrix-assisted laser desorption/ionization
time-of-flight (MALDI-TOF) mass spectrometry (detection
of covalent insulin dimers [CID]). As a matter of fact, a new
MALDI-TOF mass spectrometry procedure was developed
for both the quantification and the analysis of the primary
structure of insulin, without extensive deleterious extrac-
tion of the protein, as discussed previously.10-12 It is indeed
of utmost importance to analyze encapsulated proteins in
mild conditions so as to avoid additional stress for the
analyte. This issue has been already discussed, for instance
regarding the analysis of protein secondary structure by
Fourier transform infrared (FTIR) spectroscopy.13 It should
be noted here that the therapeutic effect of both TT and
insulin is strongly dependent on the molecular stability of
these molecules. This is the main reason why it is important
to perform qualitative analysis. On the contrary, the stabil-
ity of lysozyme was not assessed here, since it is a far less
interesting protein from the therapeutic point of view.
Finally, protein release kinetics and protein stability during
release were not assessed, since this study only focused on
the effect of the encapsulation process on the entrapped
proteins. Although the release of the protein in an active
form is an important issue, this study primarily focused
on the value of the sample preparation for analysis and
an analytical method mass spectrometry (MS) able to dis-
criminate between process-related or release-related protein
instability.
MATERIALS AND METHODS
Materials
Tetanus toxoid (batch S2545, Pasteur Mérieux, Lyon,
France), specific activity of 205 Limes factor (Lf/mg) pro-
tein, and 2,2'-azino-bis(3-ethylbenzothiazoline-6-sulfonic
acid) (ABTS) was a gift from Claire-Ann Siegrist, PhD
(Geneva, Switzerland). Porcine insulin (batch S69941607.
LGA, Novo Nordisk) was a gift from Keith Rose, PhD
(Geneva, Switzerland). Freeze-dried lysozyme, human arg-
insulin, sodium dodecyl sulfate (SDS), sodium oleate, and
α-cyano-4-hydroxycinnammic acid (α-CHCA) were ob-
tained from Sigma-Aldrich Co (Buchs, Switzerland). The
TT010 monoclonal antibody and guinea-pig antitetanus
toxoid purified IgG were made available from NIBSC
(National Institute for Biological Standards and Control,
Hertfordshire, UK). Goat anti-guinea-pig IgG-horseradish
peroxidase (HRP) conjugate (A7289) was obtained from
Sigma-Aldrich Co. Copolymers of D,L-lactide and glyco-
lide (PLGA), 50:50 molar ratio, with capped and uncapped
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carboxylic end groups (respectively, Resomer RG 503 and
RG 503 H, molecular weight [MW] gel permeation chro-
matography [GPC] of 34 kDa), as well as a capped homo-
polymer of D,L-lactide (PLA) (Resomer R 203, MW [GPC]
of 28 kDa) were purchased from Boehringer Ingelheim
(Ingelheim am Rhein, Germany). A PLA with free car-
boxylic end groups (Medisorb PLA 100 DL 4A, MW
[GPC] of 57 kDa) was provided by Alkermes (Cincinnati,
Ohio). Poly(vinyl alcohol) (PVAL, Mowiol 4–88) of MW
31 kDa, 88% hydrolyzed, was provided by Clariant Gmbh
(Frankfurt am Main, Germany). Poloxamer 407 (Lutrol
F127) was obtained from BASF (Ludwigshafen, Germany)
and povidone K30 was purchased from Fluka Chemie
(Buchs, Switzerland), together with acetonitrile (MeCN,
high-performance liquid chromatography [HPLC] grade)
and trifluoroacetic acid (TFA). All other chemicals used
were of reagent grade.
Preparation of Protein-surfactant Complexes
by Ion-pairing
Ion-pairing was in part performed as previously described
by Yoo et al.14 Briefly, lysozyme was dissolved in a pH 8.7
Tris buffer, whereas insulin was dissolved in a pH 2.5 HCl
solution. The final concentration of the solutions was of
3 mg/mL. Lysozyme and insulin were ion-paired (and thus
precipitated) at room temperature with sodium oleate and
SDS, respectively, by adding the counter-ion (previously
dissolved in the same media) in the above protein solutions.
The protein:surfactant molar ratio was 1:6 in both cases,
owing to the available positively charged residues at the
above-mentioned pH. After equilibration for 5 hours, the
suspensions were centrifuged twice for 5 minutes at 530g,
and the cakes were washed with water to remove the excess
of salts. Then, the aqueous suspensions of the complexes
were freeze dried at 0.03 mbar and at –60°C for 24 hours
(LSL Secfroid, Lyolab BII, Aclens-Lausanne, Switzerland).
In order to determine the composition of complexes (ie, the
experimental protein:surfactant molar ratio), the oleate-
lysozyme and SDS-insulin complexes were dissolved in a
1M sodium hydroxide solution and analyzed by spectro-
photometry at 281 and 291 nm, respectively (model 8453,
Hewlett Packard, Boeblingen, Germany).
Nanoparticle Preparation
Double Emulsion-solvent Evaporation Method (w1/o/w2)
Protein-loaded nanoparticles were prepared in triplicate at
2% nominal drug loading by a w1/o/w2 double emulsion-
solvent evaporation method as described previously.15
Briefly, a protein-containing aqueous phase was first poured
into a 20% organic solution of polymer (Resomer RG 503,
unless otherwise stated). Only insulin, which was insoluble
in pure water, was dissolved in a 0.1M HCl solution. The
volumes of these solutions were 100 μL and 2 mL, re-
spectively. Ethyl acetate (EtOAc) and methylene chloride
(Me2Cl2) were selected as organic solvents. Primary (w1/o)
emulsion was obtained with a 10-second sonication at
65 W (Probe sonicator, model VC 50T, Sonic and Materials
Inc, Danbury, CT). Then, 2 mL of a 2% aqueous PVAL
solution was poured into the primary emulsion and sonicated
(15 seconds, 65 W) to form the w1/o/w2 double emulsion.
The final preparation was then magnetically stirred over-
night at room temperature to evaporate the organic solvent.
The resulting nanoparticles in suspension were then
centrifuged 4 times for 15-minute cycles at 15 000g and
washed with distilled water to remove the free PVAL from
the batches. Freeze-drying of the batches was performed at
0.03 mbar and at –60°C for 24 hours.
Solid-in Oil-in Water Method (s/o/w)
Native or ion-paired proteins were directly suspended in
ethyl acetate or methylene chloride and sonicated to ob-
tain a finely dispersed solid-in oil suspension (s/o). All the
subsequent steps of nanoparticle production were the same
as those for the double emulsion method (see Double
Emulsion-solvent Evaporation Method (w1/o/w2)).
Modified Nanoprecipitation Method
As for those prepared by the emulsion-based methods, nano-
particles were prepared in triplicate and at 2% nominal
drug loading. The polymer (~200 mg) and the protein drug
(~4 mg) were dissolved either in DMSO or in N-methyl-
pyrrolidone (NMP) (~8 mL). This phase was added by
means of a syringe by inserting the needle directly into
the dispersing phase (~40 mL), which was magnetically
stirred. Nanoprecipitation occurred as soon as the protein
solution was in contact with the dispersing phase. The
dispersing phase was constituted of a solvent in which
the polymer is insoluble (water, methanol, ethanol, or pro-
panol) and contains, if needed, poloxamer 407 or polyvinyl-
pyrrolidone K30 as a surfactant. For the sake of clarity,
it should be reminded that only water is traditionally used
as dispersing phase during nanoprecipitation. Then, the
suspensions of nanoparticles were centrifuged 4 times
for 15-minute cycles at 15 000g and washed with distilled
water, in order to remove the dispersing organic medi-
um and to replace it gradually with water for subsequent
freeze-drying.
Size Determination
Particle size and polydispersity were determined by photon
correlation spectroscopy using a Zetasizer 5000 (Malvern
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Instruments Ltd, Worcestershire, UK). Nanoparticles pre-
pared by double emulsion were appropriately diluted just
after preparation with double-distilled and filtered water
(0.22 μm Millipore filter, Millipore, Billerica, MA),
whereas those prepared by nanoprecipitation were diluted
with the nonsolvent. Mean size and polydispersity were
measured 3 times for each batch.
Nanoparticle Morphology
The nanoparticle surface and shape were observed by scan-
ning electron microscopy (SEM). Samples were prepared
by finely spreading concentrated nanoparticle suspensions
over slabs and by drying them under vacuum. The samples
were then coated in a cathodic evaporator with a fine gold
layer and observed by SEM using a JSM-6400 scanning
electron microscope (JEOL, Tokyo, Japan).
Protein Loading Determination
Aliquots (20 mg) of TT-loaded nanoparticles and of those
containing the lysozyme-oleate complex were first hydro-
lysed by a 1M sodium hydroxide solution, and the resulting
solutions were spectrophotometrically measured at 291 nm.
The protein content of all other nanoparticle batches was
determined after dissolution of the carriers in DMSO. The
medium was stirred at room temperature until complete
transparency and the solution absorbance measured at
281 nm. The residual absorbance of blank nanoparticles at
this wavelength was taken into account for the calibration.
Insulin-loaded nanoparticles were also analyzed by RP-
HPLC. Accurately weighed 20-mg aliquots of nanopar-
ticles were first dissolved under mild agitation (vortex) in
300 μL of acetonitrile in test tubes. Then, 700 μL of 0.1%
TFAwere added dropwise to the above vortexed mixture to
dissolve insulin completely. The remaining undissolved
PLGA and PVAL were then separated by centrifugation at
2000g for 2 minutes. The clear supernatants were then with-
drawn, filtered through a 0.45-μm syringe filter, and analy-
zed using a RP-HPLC Waters Corp system (LC Module
1 plus, Milford, MA) equipped with a UV-visible detector.
Insulin and A21 desamido insulin were separated at room
temperature on a Nucleosil C18 column (25 mm × 4.6 inner
diameter [id], Macherey-Nagel, Oensingen, Switzerland)
packed with 5-μm particles of 100 Å pore size. The mobile
phase was an acetonitrile:water mixture (32:68) containing
0.1% TFA. The flow rate was 0.9 mL/min and the detecting
wavelength was 214 nm. The amount of A21 desamido
insulin detected in the samples was expressed as
A21 desamido insulin ð%Þ¼ AA21 desamidoinsulin
Anative insulin þ AA21 desamidoinsulin  100 ð1Þ
where A is the peak area of the considered molecule.
Each sample was assayed in triplicate. The entrapment data
were expressed as described in a previous study.16 Briefly,
drug loading (DL) refers to the amount of drug used with
respect to the amount of both polymer and drug, whereas
entrapment yield (EY) refers to the amount of recovered
drug in the final batch with respect to the amount initially
used. Nanoparticle yield (NY) is the total weight yield,
which is calculated when all nanoparticles are recovered
after freeze-drying. Entrapment efficiency (EE) is the ratio
of the final drug loading to the nominal one.
Tetanus Toxoid Antigenicity Measurements
An ELISA assay was used for estimating TT antigenicity
after exposure to stresses caused by ultrasound and organic/
aqueous interfaces. A monoclonal antibody (TT010) was
used as the capture antibody. Briefly, wells of flat-bottomed
microtiter plates (Nunc-Immuno Plate Maxisorp, Nunc,
Roskilde, Denmark) were coated with 100 μL of 1 μg/mL
monoclonal antitetanus IgG in 0.05M carbonate buffer (pH
9.6) and incubated at 4°C overnight. Nonspecific sites were
blocked with 200 μL of 1% gelatin in PBS (PBSG), and
the plates were incubated for 1 hour. The temperature was
set at 37°C for each incubation step, and the plates were
washed at least 3 times with 300 μL of a 0.05% Tween
20 solution of NaCl 0.9% after each incubation. Serial di-
lutions of reference TT and samples were prepared in a
PBS solution containing both 0.2% gelatin and 0.05%
Tween 20 (PBSTG). The wells were filled with 100 μL of
the TT reference solutions or of the samples and incubated
for 2 hours. Guinea-pig IgG (4.5 μg/mL) was added to each
well in 100 μL of PBSTG and followed by another 2-hour
incubation step. Then, 100 μL of goat anti-guinea-pig IgG-
HRP conjugate (1/5000 dilution in PBSTG) were added
to each well, and plates were incubated for an additional
1 hour. Finally, 100 μL of a 1 mg/mL HRP substrate ABTS
solution containing 30.5 mM citric acid and 0.01% H2O2
were added to the wells for the enzymatic reaction to occur.
Color was allowed to develop, and the end-point optical
density was measured at 405 nm after a 1-hour incubation
at room temperature and protection against light.
MALDI-TOF MS Sampling and Preparation of Targets
Reference solutions of increasing concentrations of insulin
were prepared in a mixture of water, acetonitrile, and TFA
(50%, 50%, and 0.1%, respectively). For nanoparticle sam-
pling, 2 mg of insulin-loaded nanoparticles were first put
in 500 μL of a 0.2% TFA acetonitrile solution for complete
polymer dissolution. Then, 500 μL of water were added to
this solution, allowing the polymer to precipitate. Quan-
tification was made possible by adding the same amount of
an internal standard (arg-insulin) to each reference solution
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as well as to each unknown sample. One microliter of each
solution was then deposited on a plate and the solvent was
allowed to evaporate under vacuum, making the drop turn
into a solid spot. One microliter of the matrix (α-CHCA) in
solution (10 mg/mL in a 0.1% TFA and 50% acetonitrile
solution) was applied on each sample spot and allowed to
dry again in the same manner. The plate was then inserted
into the mass spectrometer. MALDI-TOF MS experiments
were conducted on a MALDI-TOF instrument (Voyager
Super STR; Applied Biosystems, Foster City, CA) using a
337-nm nitrogen laser. Spectra were acquired in positive ion
linear mode (instead of reflector mode) (acceleration voltage
20 kVor 25 kV). A total of 40 shots per location (thus up to
560 shots were averaged per spot) was programmed. One
spectrum per spot was obtained and each spot was analyzed
3 times. The ratio of the relative peak height of insulin on the
peak height of arg-insulin was plotted against insulin
concentration and a linear calibration curve was generated
as reported elsewhere.10,11 Only the intensity values of the
dominant [M+H]+ peak (5777 Da) of the MS spectra was
considered for the calibration. External mass calibration was
performed on the protonated [M+H]+ ion using native por-
cine insulin.
RESULTS AND DISCUSSION
Tetanus Toxoid-loaded Nanoparticles
TT was shown to be easily entrapped within PLGA parti-
cles (Table 1). Both ethyl acetate and methylene chloride
enabled entrapment of over 70% of the initial amount of
protein, which means with entrapment efficiencies close to
95%. From this point of view, the double emulsion method
was superior to the s/o/w method. This finding is certainly
owing to a promoted drug leakage toward the outer aqueous
phase when the protein is used in the solid state. As is
often the case with the double emulsion procedure, the
nanoparticle yield was very elevated, reaching values as
high as 85%. High TT entrapment efficiencies and yields
were also observed when microspheres of 10 to 25 μm
made of polymers having different PLA:PGA ratios (50:50
and 75:25) or made of PLGA-polyoxyethylene-PLGA tri-
blocks were produced.17 Such results were also obtained
with microspheres produced by spray-drying and coacer-
vation techniques. Moreover, it was also reported that,
when TT was used in suspension rather than in solution,
the entrapment was diminished as demonstrated here (batch
TT 3).18 The nanoparticle batch TT 1 displayed the smallest
mean size value, which was to be expected since the use
of ethyl acetate always leads to smaller particles relative
to methylene chloride.16,19 Actually, in the latter case, the
preparation also contained larger particles, as shown in
Figure 1 (batch TT 2). Such a wide range of nanoparticle
size in a same population (due to methylene chloride),
along with notable antigen loading performance, might be
an advantage if a pulsed or a sustained release provided by
the larger particles is sought. Moreover, this kind of prep-
aration might be mixed with very large microspheres in
order to favor both an immediate and a prolonged release
over months. Finally, antigenic adjuvancy of encapsulating
TT cannot be excluded, as previously reported, with simi-
lar or even better effect than alum-based vaccines.20-22
Effect of Ultrasounds and Aqueous/Organic Interfaces on
TT Antigenicity
In order to evaluate the resistance of TT to sonication,
the antigen was dissolved in PBS and submitted to vari-
ous sonication durations between 5 seconds and 2 minutes
Table 1. Protein-loaded Nanoparticles Produced by s/o/w and w/o/w Methods*
Batch Emulsion Method Organic Solvent EE ± SD§ (%) EY ± SD (%) NY ± SD (%) Size ± SD (nm) PI ± SD
TT 1 w/o/w EtOAc 96.5 ± 3.9 72.3 ± 4.9 74.9 ± 4.2 353 ± 15 0.13 ± 0.13
TT 2 w/o/w Me2Cl2 93.4 ± 6.4 80.2 ± 7.3 85.8 ± 2.0 1153 ± 248 0.36 ± 0.13
TT 3 s/o/w Me2Cl2 44.3 ± 3.4 38.1 ± 3.1 85.9 ± 1.2 796 ± 108 0.34 ± 0.17
LYS A1 w/o/w EtOAc 84.4 ± 4.4 56.3 ± 11.8 66.8 ± 13.1 459 ± 49 0.18 ± 0.07
LYS A2† s/o/w EtOAc 88.0 ± 6.0 63.4 ± 5.0 72.0 ± 1.3 369 ± 14 0.16 ± 0.02
LYS A3 w/o/w Me2Cl2 112.3 ± 1.5 101.3 ± 3.6 90.4 ± 3.1 967 ± 39 0.78 ± 0.21
INS A1 w/o/w EtOAc 24.1 ± 9.5 18.4 ± 7.4 76.5 ± 2.5 425 ± 44 0.49 ± 0.21
INS A2‡ w/o/w EtOAc 25.0 ± 5.6 19.7 ± 5.1 78.6 ± 4.6 468 ± 72 0.37 ± 0.29
INS A3 w/o/w Me2Cl2 78.7 ± 10.3 69.6 ± 8.8 88.6 ± 4.3 1402 ± 584 0.66 ± 0.05
INS A4 s/o/w Me2Cl2 73.1 ± 7.7 53.7 ± 5.8 73.4 ± 0.9 1425 ± 580 0.74 ± 0.23
INS A5† s/o/w Me2Cl2 87.1 ± 17.1 68.6 ± 14.2 79.0 ± 6.3 1038 ± 126 0.74 ± 0.24
* EE indicates entrapment efficiency; SD, standard deviation (n = 3); EY, entrapment yield; NY, nanoparticle yield; PI, mean polydispersity index is
expressed using a 0 to 1 scale (n = 3); TT, tetanus toxoid; LYS, lysozyme; and INS, insulin. All batches were produced at 2% of nominal drug
loading.
† Batches Lys A2 and INS A5 were produced with the lysozyme-oleate and the SDS-insulin complexes, respectively.
‡ Batch INS A2 was produced with a 3-second sonication for the first emulsification step and a 15-second sonication for the second emulsification step.
§ All values are ±SD (n = 3). The entrapped proteins were quantified by UV spectrophotometry.
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(intensity:65W). ELISA tests showed that the antigen re-
mained particularly unaffected after 1- minute sonication
and that a slight loss of antigenicity was detectable only
after a 2-minute exposure (Figure 2). There was also no
difference between low and high sonication intensities, since
sonicated TT at 25 W during 25 seconds and 60 seconds
remained antigenically stable (95% ± 1% and 101% ± 3%,
respectively) as for samples treated at 65 W. Such an in-
sensitivity was also observed with lysozyme, the specific
activity of which was only slightly affected by sonication.23
When a protein comes into contact with a hydropho-
bic environment such as an aqueous/organic interface, the
molecule adopts a destabilized conformation, since hydro-
phobic side chains, which are normally buried in the mole-
cule core, are reversed and exposed toward the interface.
This new conformation is often responsible for subsequent
aggregation and specific activity loss of the denatured pro-
tein. Raghuvanshi et al24 have also shown that sonication
alone led to only a slight loss of immunoreactivity, where-
as sonication along with emulsification with methylene
chloride was very harmful to TT. The authors mostly as-
cribed this effect to the contributing deleterious effect of
the water/methylene chloride interface, which provoked
protein precipitation and thus concomitant antigenicity
loss. However, emulsification of TT with either ethyl ace-
tate or methylene chloride after 2-minutes of vortexing led
to very limited negative effect (Figure 3), showing that
emulsification alone cannot be held responsible for TT
antigenicity loss. It should also be pointed out that, ac-
cording to Tobio and colleagues,22,25 TT inactivation is
mostly due to the interaction of TT with PLGA and its
acidic degradation products. In another study, Alonso et al,21
who related protein aggregation with antigenicity reduc-
tion, proved that emulsification did not cause more than
14% aggregation of TT and that ethyl acetate was supe-
rior to methylene chloride in this respect, which is con-
sistent with the results obtained in Figure 3, but contrasts
with Raghuvanshi's work.24 For the sake of comparison,
TT antigenicity was totally destroyed when dissolved in
a 0.1M sodium hydroxide solution (results not shown).
Although complete alkaline digestion enables a precise
protein content determination without underestimating the
Figure 1. Scanning electron photomicrographs of batch TT 2, batch LYS A3, batch LYS B3, and batch LYS B7.
Figure 2. Effect of ultrasound on residual antigenicity of
TT dissolved in water as determined by an Elisa assay. The
sonication power input was set at 65 W.
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TT recovered amount,26 this method is not suitable for
antigenicity determination, nor is acid digestion, which de-
stroyed ~30% of TT antigenicity as reported elsewhere.27
The alkaline digestion method was shown to be deleterious
for diphtheria toxoid also.28
Lysozyme-loaded Nanoparticles
Lysozyme is a small, 129-residue protein (MW:14 300 Da).
It is a water soluble protein, and in this respect lysozyme
might suffer from drug leakage into the external aqueous
phase during encapsulation by the w/o/w double emul-
sion method. Despite this known negative effect, lysozyme
was quite well retained within nanoparticles when this
method was used (batches LYSA1 andA3, Table 1; Figure 1).
Nevertheless, in order to minimize even more drug leakage,
it is possible to modify protein solubility by an ion-pairing
technique.4 In substance, the electrostatic interaction be-
tween a positively charged peptide or protein and an anionic
detergent renders the drug more hydrophobic. Ion-pairing
was shown to increase the solubility of proteins such as neu-
rotensin, bradykinin, or insulin in various organic solvents.3,29
Lysozyme was previously successfully ion-paired with
sodium oleate, as reported by Yoo et al.14 It was claimed
that the resulting complex was more easily dissolved in
polar organic solvents such as DMSO than free lysozyme
and hence that increased loading could be achieved when
formulated through a modified nanoprecipitation method.
Moreover, it was shown that complexed lysozyme ex-
hibited improved conformational stability in organic sol-
vents and at elevated temperatures. It was postulated that the
ion-paired oleate molecules were able to diminish protein
mobility and therefore to prevent lysozyme unfolding to
some extent. It should be noted that preventing protein
unfolding might also avoid the exposure of buried hydro-
phobic regions and therefore reduce nonspecific protein
adsorption onto polymer surface, as discussed elsewhere.30
In the present work, a lysozyme-oleate complex was used
in a s/o/w method to study the effect on the protein final
loading and compared with free lysozyme when processed
via a w/o/w method. Indeed, it was thought that the hydro-
phobic complex should be less prone than free lysozyme
to leak out into the external aqueous phase. The complex
contained 87% ± 1% (wt/wt) of lysozyme (which is very
close to the theoretical 89% value expected for a protein/
surfactant ratio of 1:6) and high powder recovery after
freeze-drying was achieved, reaching 83%. As shown in
Table 1 (batch LYS A2), however, this strategy had no real
influence on entrapment efficiency. Contrasting with the s/
o/w suspension method, direct dissolution of ion-paired
leuprolide in the organic phase by means of a cosolvent
such as NMP enabled the entrapment efficiency to increase
from 75% to 96%.6
Aside from the emulsion-based methods mentioned above,
a modified nanoprecipitation technique was also used for
lysozyme entrapment.2 Among the solvents investigated,
DMSO and methanol were reported as being well adapted
for lysozyme dissolution,1,31 but preliminary dissolution
testing showed that only DMSO accurately dissolved this
protein (results not shown). This discrepancy is generally
ascribed to the way the commercially available protein was
freeze-dried. Actually, the protein solubility in some polar
organic solvents can be increased if the pH of the protein
solution prior to freeze-drying is set at a value far from the
protein isoelectric point. Since lysozyme was soluble in
DMSO and insoluble in many alcohols, we attempted to
entrap it by using DMSO as solvent (ie, the diffusing phase)
and an alcohol as nonsolvent (ie, the dispersing phase). Most
of the time, the entrapment efficiencies were better than
when the nonsolvent was water (Table 2) despite lower
nanoparticle yields. Similar loadings but different nano-
particle mean sizes were achieved with methanol, ethanol,
and propanol as nonsolvents (batches LYS B2, B3, and B7;
Figure 1). This effect of the nonsolvent on the mean size
confirmed the results already observed in a previous study
with blank nanoparticles.2 As often observed with the
double emulsion method employed for protein entrapment,
the use of polymers with uncapped carboxylic groups fa-
vors high entrapment efficiencies (batches LYS B4 and
B6 vs batches LYS B3 and B5), suggesting that ionic in-
teraction between lysozyme and polymer plays an impor-
tant role in the protein loading even in this anhydrous
protocol. The PLGA copolymer was superior in terms of
final loading to the more hydrophobic PLA homopolymer
(batches LYS B4 vs LYS B6). In fact, batch LYS B4
Figure 3. Effect of aqueous/organic solvent interfaces
on residual TT antigenicity as determined by an Elisa assay
(mean ± SD, n = 3).
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displayed the best loading characteristics. Moreover, these
nanoparticles are very small and show narrow size distribu-
tion. It should also be noted that some of the batches
produced required no surfactants (except for batches LYS
B1, B5, and LYS B7). In comparison, a different method,
involving first lysozyme dissolution in a methylene chloride/
DMSO mixture containing also PLGA, then the emulsi-
fication of this solution into an aqueous phase, led to
microspheres (∼ 10 μm) with entrapment efficiencies in-
creasing along with increasing DMSO proportion.32
Insulin-loaded Nanoparticles
Insulin is a small protein composed of 2 polypeptide chains
linked by 2 disulfide bridges. The A-chain is made of
21 amino acids and the B-chain contains 30 amino acids.
Insulin is only sparingly soluble in water and for it to be
entrapped by the w1/o/w2 or by the nanoprecipitation
method, it is mandatory to set the aqueous pH below the
insulin isoelectric point (pI ) (pI = 5.5), where the basic
amino groups become protonated. An acidic environment
is also required for ion-pairing to take place with all 6
basic functionalities of insulin being positively charged (at
pH 2.5). These groups can thus fully interact with the
anionic part of SDS at a protein/surfactant ratio of 1:6.33
The obtained complex contained 82% ± 1% (wt/wt) of
insulin (theoretical value = 78%), and powder recovery
after freeze-drying reached 75%. In contrast to lysozyme,
insulin was not efficiently entrapped in nanoparticles
when ethyl acetate was used during the double emulsion
procedure (batches INS A1 and A2, Table 1), whereas
methylene chloride was able to improve protein loading
(batch INS A3). The duration of sonication had no effect
on entrapment efficiency, as reported in a previous study
concerning bovine serum albumin entrapment.16 Entrap-
ment efficiencies for insulin reported in other studies
using emulsion-based methods vary from 14% to 97% de-
pending on the manufacturing conditions. Generally, using
methylene chloride, PLA, a small internal w1 phase, or
low initial drug loading leads to better results.34-36 When
insulin was entrapped in large microparticles (~200 μm),
very high insulin entrapment efficiencies (near 100%)
could be obtained.37,38 Concerning the s/o/w method,
free insulin was not interesting for augmenting the
loading level (batches INS A4 and A5) and the more
hydrophobic SDS-insulin ion-pair was inefficient too,
despite an improved solubility in some solvents such as
1-octanol.5
By using nanoprecipitation as described by Yoo et al,14
insulin entrapment efficiency was comparable to the level
obtained with double emulsion and when using ethyl ace-
tate as solvent (batch INS B1, Table 2). Classical nano-
precipitation (with acetone as diffusing solvent) was shown
to produce nanoparticles containing approximately the same
amount of insulin.9 When small nanoparticles are required
(and hence, when it is necessary to use an entrapment meth-
od such as nanoprecipitation), improving insulin loading
still remains a difficult task.39 Using ethanol, in which in-
sulin is also insoluble, instead of water as dispersing me-
dium did not give a satisfactory result (batch B2). With
respect to the solvents, a trial with NMP in place of DMSO,
resulted in a significant negative impact on protein loading
(batch INS B3). However, a polymer with free carboxylic
end groups (batch INS B4) enabled similar entrapment as
Table 2. Protein-loaded Nanoparticles Produced by Nanoprecipitation*
Batch Polymer‡ Nonsolvent EE ± SD§ (%) EY ± SD (%) NY ± SD (%) Size ± SD (nm) PI ± SD
LYS B1† PLGA Water 40.2 ± 1.7 36.4 ± 0.02 90.7 ± 1.5 279 ± 17 0.19 ± 0.08
LYS B2 PLGA Methanol 47.4 ± 5.0 34.7 ± 4.6 72.7 ± 4.6 137 ± 3 0.21 ± 0.01
LYS B3 PLGA Ethanol 56.0 ± 1.9 37.9 ± 2.6 67.4 ± 6.6 229 ± 3 0.13 ± 0.01
LYS B4 PLGA H Ethanol 91.2 ± 4.4 52.9 ± 2.8 58.6 ± 5.7 202 ± 5 0.14 ± 0.01
LYS B5† PLA Ethanol 34.6 ± 5.3 16.8 ± 1.5 42.6 ± 5.0 351 ± 26 0.07 ± 0.01
LYS B6 PLA H Ethanol 59.9 ± 13.8 30.0 ± 4.3 58.5 ± 8.6 237 ± 7 0.15 ± 0.02
LYS B7† PLGA Propanol 43.3 ± 4.9 27.2 ± 7.2 62.4 ± 13.0 567 ± 140 0.29 ± 0.29
INS B1† PLGA Water 22.8 ± 5.5 9.3 ± 3.1 40.0 ± 4.3 133 ± 8 0.14 ± 0.02
INS B2† PLGA Ethanol 13.5 ± 5.0 1.5 ± 4.0 11.5 ± 3.4 173 ± 10 0.11 ± 0.01
INS B3† PLGA Ethanol G 2 G 1 29.2 ± 3.6 169 ± 19 0.14 ± 0.02
INS B4 PLA H Ethanol 17.6 ± 3.2 9.7 ± 4.0 55.3 ± 10.3 302 ± 6 0.18 ± 0.04
* EE indicates entrapment efficiency; SD, standard deviation (n = 3); EY, entrapment yield; NY, nanoparticle yield; PI, mean polydispersity index is
expressed using a 0 to 1 scale (n = 3); LYS, lysozyme; INS, insulin; All batches were produced at 2% of nominal drug loading.
† The Solvent used for nanoparticle production was DMSO, except for batch INS B3 (N-methylpyrrolidone). Batches LYS B1, LYS B5, INS B1, and
INS B2 required 1% poloxamer 407 dissolved in the nonsolvent, whereas povidone K30 (2%) was necessary for batch LYS B7.
‡ PLGA indicates poly(D,L-lactic-co-glycolic acid); PLGA H stands for PLGA copolymer containing uncapped carboxylic end groups; PLA for poly
(D,L-lactic acid); and PLA H for PLA with uncapped carboxylic end groups. The polymers used were Resomer RG 503 (PLGA); Resomer R 203
(PLA); Resomer RG 503 H (PLGA H); and Medisorb PLA 100 DL 4A (PLA H).
§ All values are ±SD (n = 3). Entrapped proteins were quantified by UV spectrophotometry.
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for batch INS B1. This last example illustrates again that
ionic interactions might promote protein entrapment in
nanoprecipitation, as observed above with lysozyme (batch
LYS B6). In this respect, it is noteworthy that PLGA and
PLA H exhibited in both cases (with lysozyme as well as
with insulin) the same capacity of protein retention. As
expected, the size of the resultant carriers is comparatively
smaller and more monodisperse than when nanoparticles
were obtained by double emulsion, confirming the results
previously obtained with unloaded nanoparticles.2
Insulin chemical stability was also investigated. Insulin
mainly suffers from 2 major degradation pathways.40 In acid
media (pH ~ 2–3), some amino acids undergo deamidation.
Statistically, the last amino acid of the A-chain (aspa-
ragine A21) preferentially deamidates, leading to the so-
called A21 desamido insulin. In less acid environments
(pH ~ 4–5), CIDs are formed, this degradation pathway
being favored with respect to deamidation.41,42 Usually,
the deamidated by-products are separated from insulin by
RP-HPLC, whereas CID are detected and quantified by
size exclusion HPLC.43 In this work, A21 desamido insu-
lin was analyzed with a classical RP-HPLC method, but
a new MALDI-TOF MS method was used to check for
CID in nanoparticles.10 In fact, this method was shown to
be an outstanding analytical tool that is able to provide
accurate qualitative information along with precise drug
quantification (Table 3), provided that an appropriate in-
ternal standard is added in the final mixture to counteract
signal variability. Sampling is rapid, easy and is performed
in rather mild conditions, which simply require dissolution
of the carrier in an adapted medium. The amount of A21
desamido insulin measured in nanoparticles ranged be-
tween 1.1% and 2.1% and complies with data from
literature.37 Only batch INS B4 contained a slightly higher
amount of deamidated insulin (3.3 ± 1.0%). The small
amounts of deamidated products and the detected traces of
CID might be the result of the slow rate of by-product
formation, as reported elsewhere.37,40 As already men-
tioned, insulin needed to be dissolved in an acid solution
during the w/o/w procedure, but the solution was used
immediately and such working conditions were therefore
not damaging enough to induce formation of high per-
centages of A21 desamido insulin. As a matter of fact,
since even deamidated insulin retains more than 90% of
its native potency, it is possible to claim that entrapped
insulin within nanoparticles could be considered as fully
biologically active, but only provided insulin does not
suffer from fibrillation. Indeed, it should be mentioned
that insulin is liable to be inactivated through physical
degradation such as fibrillation. However, this aspect was
not investigated here, since this study only focused on in-
sulin chemical degradation.
CONCLUSIONS
The results obtained from these studies revealed that nano-
precipitation can sometimes be a good alternative to the
classical and widely used double emulsion method. This is
a valuable method for protein entrapment (especially for
lysozyme) leading to small and highly loaded nanoparti-
cles. In this connection, the use of solvents such as DMSO
(instead of acetone or ethanol) and the use of nonsolvents
such as methanol or ethanol (instead of water) certainly pro-
mote the formation of a narrow population of nanopar-
ticles. It has also been demonstrated that MALDI-TOF
mass spectrometry is an outstanding analytical method for
both drug content determination and molecular stability
study. The accuracy of the method matched that obtained
with liquid chromatography and sampling did not require
long and damaging steps.
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Table 3. Entrapment Efficiencies of Insulin in Nanoparticles
Obtained From UV Spectroscopy, RP-HPLC and MALDI-TOF
MS*
Batch† EE ± SD‡(%)
UV Spectroscopy RP-HPLC MALDI-TOF MS
INS A1 24.1 ± 9.5 20.1 ± 4.1 25.9 ± 4.9
INS A2 25.0 ± 5.6 20.2 ± 4.5 23.2 ± 2.7
INS A3 78.7 ± 10.3 74.9 ± 6.2 72.5 ± 6.1
INS A4 73.1 ± 7.7 60.7 ± 8.6 65.4 ± 12.2
INS B2 13.5 ± 5.0 8.1 ± 2.7 11.0 ± 2.2
INS B3 G 2 G 1 nd
INS B4 17.6 ± 3.2 13.9 ± 1.9 13.0 ± 2.0
* RP-HPLC indicates reverse phase-high-performance liquid
chromatography; MALDI-TOF MS, matrix-assisted laser desorption/
ionization time-of-flight mass spectrometry; EE, entrapment efficiency;
INS, insulin; and nd, not detected.
† Batches: A, obtained by an emulsion-based method; B, obtained by
nanoprecipitation.
‡ All values are ±SD (n = 3).
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